{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG000","lowerLimit":"1.6","upperLimit":"NA","value":"8.5"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG001","lowerLimit":"4.0","upperLimit":"NA","value":"13.5"},{"groupId":"OG002","lowerLimit":"2.4","upperLimit":"20.8","value":"7.1"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG003","lowerLimit":"6.3","upperLimit":"NA","value":"15.9"},{"groupId":"OG004","lowerLimit":"6.7","upperLimit":"14.5","value":"10.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"25"}],"units":"Participants"}],"description":"OS was defined as the time (in months) from the date of first dose of study drug to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at the date of last contact. OS was analyzed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG000","title":"Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG001","title":"Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received PF-04518600 3.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.","id":"OG002","title":"Combination B Phase 1b: PF-04518600 3.0 mg/kg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG003","title":"Combination B Phase 2 NSCLC: PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 2 participants with SCCHN received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W.","id":"OG004","title":"Combination B Phase 2 SCCHN: PF-04518600 0.3 mg/kg + Avelumab"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all enrolled participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug to date of death from any cause or data censoring date, whichever occurred first (maximum up to 7.3 years)","title":"OS for Combination B","type":"SECONDARY","unitOfMeasure":"Months"}